JAPMA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fridman, R.
Right arrow Articles by Weil, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fridman, R.
Right arrow Articles by Weil, L., Jr.
Journal of the American Podiatric Medical Association
Volume 99 Number 3 191-193 2009
Copyright © 2009 American Podiatric Medical Association

Extracorporeal Shockwave Therapy for Interdigital Neuroma

A Randomized, Placebo-Controlled, Double-Blind Trial

Robert Fridman, DPM *, Jarrett D. Cain, DPM, MSc {dagger} and Lowell Weil, Jr., DPM, MBA {ddagger}

* Department of Orthopaedic Surgery, Columbia University Medical Center, New York, NY; private practice, New York, NY.
{dagger} Private practice, Yeadon, PA.
{ddagger} Weil Foot and Ankle Institute, Des Plaines, IL.

Corresponding author: Lowell Weil, Jr., DPM, MBA, Weil Foot and Ankle Institute, 1455 Golf Rd, Des Plaines, IL 60016. (E-mail: weiljr{at}aol.com)

Abstract

Background: We sought to evaluate the safety and effectiveness of extracorporeal shockwave therapy as a therapeutic treatment for destroying Morton’s neuroma.

Methods: Twenty-five patients (25 feet) were included in the study. Indications for participation were more than 8 months of conservative care with a visual analog scale pain score of 4 or greater. The mean overall pain score on a modified visual analog scale was 6.9 preoperatively.

Results: Thirteen patients were randomized to the active group and 12 to the sham group. Two patients in the sham group were lost to follow-up. Post-treatment evaluations were performed at 1, 6, and 12 weeks by a blinded investigator (L.W.). The end point evaluation parameter was the reduction in visual analog scale score. The treatment group showed a significant difference before and after extracorporeal shockwave therapy (P < .0001). The sham group did not have a significant difference after 12 weeks (P = .1218).

Conclusions: Extracorporeal shockwave therapy is a possible alternative to surgical excision for Morton’s neuroma. (J Am Podiatr Med Assoc 99(3): 191–193, 2009)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Podiatric Medical Association.